|
82
|
279
|
5ap6A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
86
|
264
|
5ew9A |
Crystal structure of aurora a kinase domain bound to mk-5108 |
|
102
|
303
|
5e8wA |
Tgf-beta receptor type 1 kinase domain (t204d) in complex with staurosporine |
|
84
|
280
|
5ei8A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
100
|
303
|
5e8zA |
Tgf-beta receptor type 1 kinase domain (t204d) in complex with 3-amino-6-[4-(2-hydroxyethyl)phenyl]-n-[4-(morpholin-4-yl)pyridin-3-yl]pyrazine-2-carboxamide |
|
93
|
309
|
4zseA |
Crystal structure of egfr 696-1022 t790m/v948r, crystal form ii |
|
79
|
298
|
5ankA |
Crystal structure of cdk2 in complex with 2,4,6-trioxo-1-phenyl- hexahydropyrimidine-5-carboxamide processed with the crystaldirect automated mounting and cryo-cooling technology |
|
83
|
264
|
5dt4A |
Aurora a kinase in complex with aa35 and atp in space group p6122 |
|
84
|
264
|
5dr2A |
Aurora a kinase in complex with aa30 and atp in space group p6122 |
|
82
|
264
|
5dt0A |
Aurora a kinase in complex with jnj-7706621 in space group p6122 |
|
75
|
297
|
5angA |
Crystal structure of cdk2 in complex with 7-hydroxy-4-(morpholinomethyl)chromen-2-one processed with the crystaldirect automated mounting and cryo-cooling technology |
|
81
|
264
|
5drdA |
Aurora a kinase in complex with atp in space group p6122 |
|
80
|
264
|
5dr6A |
Aurora a kinase in complex with aa30 and jnj-7706621 in space group p6122 |
|
117
|
464
|
5dvrA |
Crystal structure of tgcdpk1 from toxoplasma gondii complexed with gw780159x |
|
81
|
297
|
5aniA |
Crystal structure of cdk2 in complex with 6-chloro-7h-purine processed with the crystaldirect automated mounting and cryo-cooling technology |
|
88
|
297
|
5amnA |
The discovery of 2-substituted phenol quinazolines as potent and selective ret kinase inhibitors |
|
84
|
263
|
5dpvA |
Aurora a kinase in complex with aa35 and jnj-7706621 in space group p6122 |
|
84
|
298
|
5aneA |
Crystal structure of cdk2 in complex with 6-methoxy-7h-purine processed with the crystaldirect automated mounting and cryo-cooling technology |
|
82
|
264
|
5dr9A |
Aurora a kinase in complex with aa29 and jnj-7706621 in space group p6122 |
|
82
|
264
|
5dt3A |
Aurora a kinase in complex with atp in space group p6122 |
|
85
|
296
|
5anjA |
Crystal structure of cdk2 in complex with n-(9h-purin-6-yl)thiophene- 2-carboxamide processed with the crystaldirect automated mounting and cryo-cooling technology |
|
84
|
273
|
5drbA |
Crystal structure of wnk1 in complex with wnk463 |
|
81
|
274
|
5dwrA |
Identification of n-(4-((1r,3s,5s)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (pim447), a potent and selective proviral insertion site of moloney murine leukemia (pim) 1,2 and 3 kinase inhibitor in clinical trials for hematological malignancies |
|
78
|
293
|
5andA |
Crystal structure of cdk2 in complex with 2-imidazol-1-yl-1h- benzimidazole processed with the crystaldirect automated mounting and cryo-cooling technology |
|
79
|
273
|
5diaA |
Pim1 in complex with cpd36 ((1s,3s)-n1-(6-(5-(pyridin-3-yl)-1h-pyrazolo[3,4-c]pyridin-3-yl)pyridin-2-yl)cyclohexane-1,3-diamine) |
|
83
|
264
|
5dosA |
Aurora a kinase in complex with aa35 and atp in space group p6122 |
|
87
|
281
|
5de2A |
Structural mechanism of nek7 activation by nek9-induced dimerisation |
|
80
|
273
|
5dgzA |
Discovery of 3,5-substituted 6-azaindazoles as potent pan-pim inhibitors |
|
89
|
264
|
5da3A |
Crystal structure of ptk6 kinase domain with inhibitor |
|
92
|
317
|
5d41A |
Egfr kinase domain in complex with mutant selective allosteric inhibitor |
|
84
|
265
|
5dn3A |
Aurora a in complex with atp and aa35. |
|
83
|
273
|
5dhjA |
Pim1 in complex with cpd4 (3-methyl-5-(pyridin-3-yl)-1h-pyrazolo[3,4-c]pyridine) |
|
85
|
309
|
5am6A |
Native fgfr1 with an inhibitor |
|
85
|
265
|
5dnrA |
Aurora a kinase in complex with atp in space group p41212 |
|
78
|
265
|
5dlsA |
Identification of novel, in vivo active chk1 inhibitors utilizing structure guided drug design |
|
76
|
301
|
5dbxA |
Crystal structure of murine spak(t243d) in complex with amppnp |
|
90
|
307
|
5am7A |
Fgfr1 mutant with an inhibitor |
|
97
|
293
|
5dfpA |
Crystal structure of pak1 in complex with an inhibitor compound frax1036 |
|
89
|
268
|
5d7vA |
Crystal structure of ptk6 kinase domain |
|
84
|
297
|
5di1A |
Map4k4 in complex with an inhibitor |
|
100
|
295
|
5dewA |
Crystal structure of pak1 in complex with an inhibitor compound 5 |
|
88
|
300
|
5d7aA |
Crystal structure of the kinase domain of traf2 and nck-interacting protein kinase with ncb-0846 |
|
88
|
297
|
5dg5A |
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with altiratinib analog dp-4157 |
|
76
|
289
|
5dh3A |
Crystal structure of mst2 in complex with xmu-mp-1 |
|
79
|
299
|
5d9hA |
Crystal structure of spak (stk39) dimer in the basal activity state |
|
94
|
295
|
5deyA |
Crystal structure of pak1 in complex with an inhibitor compound g-5555 |
|
86
|
269
|
4zogA |
Vx-680/mk-0457 binds to human abl1 also in inactive dfg conformations. |
|
107
|
402
|
4yzdA |
Crystal structure of human phosphorylated ire1alpha in complex with adp-mg |
|
94
|
277
|
5cxhA |
Syk catalytic domain complexed with a potent orally bioavailable thiazole inhibitor |
|
60
|
276
|
4yzmA |
Humanized roco4 bound to lrrk2-in1 |
